x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:21:59

Experts Answer Questions on Personalized Management...

Decera Clinical Education Oncology Podcast ·

2023/02/17

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including: Practical use of the Molecular International Prognostic Scoring System Mutational targets and other treatments in ongoing clinical trialsProphylaxis with venetoclax therapyBest practices for bone marrow transplant, including induction and salvage

en

00:36:17

Individualizing Care for Patients With...

Decera Clinical Education Oncology Podcast ·

2023/01/18

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC Current data and treatment strategies and the future of antibody–drug

en

00:15:51

Contemporary Approaches to Treating Polycythemia...

Decera Clinical Education Oncology Podcast ·

2023/01/11

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:Patient presentation and goals of frontline therapyConsiderations for second-line therapy in the setting of treatment intoleranceExperts’ thoughts on the potential of early intervention to alter disease progressionPresenters:Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia

en

00:31:24

HCC Surveillance: Challenges and Opportunities

Decera Clinical Education Oncology Podcast ·

2023/01/03

In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance. Presenters:David E. Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineChief, Hepatology Section Division of Gastroenterology and Hepatology University of PennsylvaniaDirector of HepatologyCorporal

en

00:09:23

A Patient’s Perspective on Effective Communication...

Decera Clinical Education Oncology Podcast ·

2022/12/13

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience. Presenter:Zoe LanhamPatientLink to full program:https://bit.ly/3Fukjzk

en

00:27:21

Expert Thoughts on Studies of Interest Presented at...

Decera Clinical Education Oncology Podcast ·

2022/11/29

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial •

en

00:46:35

The Transgender Cancer Experience: A Conversation...

Decera Clinical Education Oncology Podcast ·

2022/11/29

In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include:4 aspects of transgender care: emotional, social, medical, legalGetting language right and how to gracefully recover from fumblesSensitively approaching ongoing cancer care in transmasculine and

en

00:10:33

Evolving Role of BTK Inhibitors in CLL: Experts...

Decera Clinical Education Oncology Podcast ·

2022/11/09

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial todayRelevance of overall response rate vs progression-free survival for BTK inhibitor therapyApproval of ibrutinib/venetoclax combination

en

00:21:46

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/10/28

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic

en

01:18:59

Relapsed/Refractory Myeloma: Navigating the Complex...

Decera Clinical Education Oncology Podcast ·

2022/10/24

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:How to sequence currently available therapies after relapseChallenges with using BCMA-targeted agents in clinical practiceExperts’ thoughts on the potential approval of bispecific agentsPresenters include:Paul G

en

00:15:21

Expert Thoughts on Key Trials of Interest for Ovarian...

Decera Clinical Education Oncology Podcast ·

2022/10/24

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancerPhase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancerPhase III ARIEL3: final OS for

en

00:19:39

Expert Insights on Key Updates From the 2022 ESMO...

Decera Clinical Education Oncology Podcast ·

2022/10/04

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placeboPhase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced

en

00:29:48

Managing EGFR-Mutated Non-Small-Cell Lung Cancer in...

Decera Clinical Education Oncology Podcast ·

2022/09/28

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:• Identifying patients who may benefit the most from adjuvant osimertinib • Testing for EGFR mutations in early-stage NSCLC• Critical importance of getting molecular test results before starting immunotherapy• Monitoring cardiac toxicity in patients receiving osimertinib• Key

en

00:28:34

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/08/30

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SEQUOIA: phase III study evaluating cohort

en

00:26:12

Experts Discuss Challenges in Advanced Hepatocellular...

Decera Clinical Education Oncology Podcast ·

2022/08/22

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:Factors to consider before selecting frontline immunotherapyRole of TKIs in the frontlineImpact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapyReal-world evidence on frontline immunotherapy/VEGF combination therapyFactors

en

00:39:32

HER2-Positive Breast Cancer: Current Approaches for...

Decera Clinical Education Oncology Podcast ·

2022/07/28

In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes: Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and riskSequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central

en

00:26:22

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/07/21

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLLFLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes

en

00:32:16

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/07/06

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of: The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL3-year follow-up analysis from the CAPTIVATE

en

00:38:27

Expert Insights on New Data From ASCO 2022 Informing...

Decera Clinical Education Oncology Podcast ·

2022/06/30

In this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and cervical cancers regarding:Subgroup analyses from KEYNOTE-826 evaluating pembrolizumab in combination with chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancerPreliminary subgroup analyses from phase III ENGOT-EN5/GOG-3055 SIENDO trial of selinexor vs placebo maintenance in recurrent endometrial cancerUpdated

en

00:46:39

Expert Insight on Key Data From SGO 2022 Informing...

Decera Clinical Education Oncology Podcast ·

2022/05/19

In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancerFinal OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm

en

224 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College